A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia

MLA

Ryan, Christine E., et al. “A Phase 1b Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.” Leukemia, no. Preprints, Jan. 2023, pp. 1–8. EBSCOhost, https://doi.org/10.1038/s41375-023-01830-2.

APA

Ryan, C. E., Brander, D. M., Barr, P. M., Tyekucheva, S., Hackett, L. R., Collins, M. C., Fernandes, S. M., Ren, Y., Zhou, Y., McDonough, M. M., Walker, H. A., McEwan, M. R., Abramson, J. S., Jacobsen, E. D., LaCasce, A. S., Fisher, D. C., Brown, J. R., & Davids, M. S. (2023). A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia, Preprints, 1–8. https://doi.org/10.1038/s41375-023-01830-2

Chicago

Ryan, Christine E., Danielle M. Brander, Paul M. Barr, Svitlana Tyekucheva, Liam R. Hackett, Mary C. Collins, Stacey M. Fernandes, et al. 2023. “A Phase 1b Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.” Leukemia, no. Preprints (January): 1–8. doi:10.1038/s41375-023-01830-2.